Navigation Links
First Patient Dosed in Phase I Clinical Trial using RoosterBio’s Cellular Starting Materials
Date:3/4/2020

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today a significant milestone in the regenerative medicine field with the dosing of the first patient using its innovative cellular starting materials. The patient has been treated by RoosterBio’s pharmaceutical customer with an Investigational New Drug (IND) that was manufactured using RoosterBio’s CliniControl cell and media systems. This marks the first demonstration of standardized off-the-shelf cellular starting and ancillary raw materials and associated scalable biomanufacturing applied to regenerative medicine therapeutic products.

“The first-in-human clinical trial of our customer’s novel therapeutic manufactured using our CliniControl products is an important milestone and a key step to tangibly demonstrate RoosterBio’s commitment to helping our customers rapidly develop safe and effective regenerative medicine products,” said Margot Connor, CEO of RoosterBio. “More importantly, this platform advancement will fuel the rapid commercialization of scalable regenerative cures.”

The use of RoosterBio’s CliniControl products is supported by Type II Master Files (MF) which were submitted to the U.S. Food and Drug Administration (FDA) in 2017 for bioprocessing media and 2018 for hMSC banked vials. As a result, the FDA has on-file the proprietary chemistry, manufacturing and controls (CMC) information for RoosterBio’s starting cell banks and bioprocess media systems for simple referencing by its therapeutic sponsors.

RoosterBio now has five customers who have been granted authorization to cross reference both of its MFs as part of their customers’ clinical development. RoosterBio has radically simplified product development and shortened product development timelines by providing access to standardized, off-the-shelf, ancillary and cellular starting materials manufactured under current good manufacturing (cGMP) conditions for further manufacturing and regulatory compliancy. RoosterBio’s focus on industrializing the regenerative medicine supply chain ushers in a new era of productivity to the field.

Connor added, “We are excited to see RoosterBio’s vision of solving regenerative medicine product and process development challenges with innovative biomanufacturing strategies, continue to drive novel therapeutic approaches forward.”

About CliniControl™ Products
CliniControl cells and media are the first and only off-the-shelf, cGMP-produced human mesenchymal stem/stromal cells (hMSCs) and bioprocess media systems with accompanying Type II Master Files on record with the U.S. Food and Drug Administration (FDA). CliniControl products radically simplify the process of IND filing and clinical translation for Regenerative Medicine companies that utilize hMSCs within their manufacturing process.

About RoosterBio, Inc.
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization to the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.

Read the full story at https://www.prweb.com/releases/first_patient_dosed_in_phase_i_clinical_trial_using_roosterbios_cellular_starting_materials/prweb16955951.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Dell Laser Consultants is Among the First in Texas to offer the RxSight™ Light Adjustable Lens to Patients
2. Accelera Canada, a Full-Service Firm, Opens First Office in Toronto
3. First Alzheimer’s Disease Gene Therapy Human Study Provided by Maximum Life Foundation, Offers 10 Free Therapies for Qualifying Patients
4. Personalized Stem Cells, Inc. Announces First Patients Treated in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
5. Burlington Medical Develops the First-of-Its-Kind Radiation Protection Garment Exclusively for Women
6. The first International Sigma Anti-Bonding Calcium Symposium (ISACS 2019) by CBHI
7. Personalized Stem Cells, Inc. Announces First Patients Enrolled in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
8. Deep Science Ventures Launches Europe’s First Venture-Building Programme for Food & Agriculture
9. VetStem Biopharma Secures FDA Approval of First Human IND for its Subsidiary, Personalized Stem Cells, Inc.
10. Landsec and Spartan Bioscience Trial the World’s First On-Site Legionella DNA Test in the UK
11. Swiss Biotech Gnubiotics, Announces Global Launch of GNU100 the First Microbiome Specialty Ingredient for Companion Animal Gut Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2020)... , ... March 02, 2020 , ... Toronto-based clinical research ... soon opening its newest office location just 5 minutes south of Clarksburg on a ... on the property, called End of the Rainbow Orchard, and decided it would be ...
(Date:2/28/2020)... , ... February 28, 2020 , ... Meridian Clinical ... 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. Meridian is ... for the Best Clinical Trial Network award. These nominations were the result of two ...
(Date:2/28/2020)... ... February 27, 2020 , ... ... newest portfolio company. Established to develop and commercialize a manufacturing platform for ... Mexico State University (NMSU). The patent-pending technology results in membranes with controllable ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... March 10, 2020 , ... ... biopharmaceutical engineering firm, is pleased to announce the addition of Carson Dickey ... device qualification and validation in the biopharmaceutical cold chain. He provides design ...
(Date:3/3/2020)... , ... March 03, 2020 , ... ... the pharmaceutical, biotech and medical device industries, was recognized by INC. 5,000 on ... forward annual lists to note industry leaders greatly impacting their spheres of influence ...
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing its ... published the results of its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) ... human milk. These complex carbohydrates are indigestible and therefore function as a prebiotic ...
(Date:2/21/2020)... ... 2020 , ... Join Forrest Brown, Engineering Services Manager – Northeast Region and ... an informative session on Wednesday, February 26, 2020 at 1pm EST to ... facility design to add manufacturing flexibility in the future, especially for CMOs , ...
Breaking Biology Technology: